The possibilities of multimodal neuroprotection in patients with chronic brain ischemia against the background of arterial hypertension and atherosclerosis

Authors:
I.A. GRIBACHEV, T.F. POPOVA, E.V. PETROVA, A.V. ZVONKOVA

FSBEI in Novosibirsk State Medical University of the Ministry of Health of Russia

Place of publication:
NEUROLOGY, NEUROPSYCHIATRY, PSYCHOSOMATICS. 2023;15(2):19–26

Abstract:
Chronic cerebrovascular disease manifests itself through a combination of cognitive, emotional, and autonomic impairments. Accurate and timely assessment and diagnosis of emotional and autonomic disorders, as well as their timely correction, are important for slowing the progression of cognitive impairment.

The aim of the study was to investigate the efficacy and safety of Mexidol administered intravenously by drip (500 mg once a day) for 14 days, followed by oral administration of Mexidol FORTE 250 at a dose of 250 mg 3 times a day for 60 days in middle-aged patients with chronic cerebral ischemia (CCI) against the background of arterial hypertension and atherosclerosis.

Material and methods. The open observational program included 60 patients aged 45 to 59 years with chronic cerebral ischemic hemisphere formation, confirmed by the results of neuropsychological and neuroimaging examination. They received Mexidol initially intravenously (14 days), and then in tablet form - Mexidol FORTE 250 (60 days). Patients underwent neuropsychological testing, assessment of the level of reactive and personal anxiety (Spielberger-Khanin Anxiety Scale), the nature of vegetative support (Vein Autonomic Response Scale as modified by V.L. Golubev), the severity of general, mental and physical asthenia (MFI-20 questionnaire) and quality of life (MOS SF-36 questionnaire).

Results. The results of the treatment showed relief of asthenic syndrome and autonomic dysfunction with Mexidol. The differences were statistically significant both compared to baseline and when compared to the control group (p

Conclusion. Patients with chronic cerebral ischemia (CCI) experience significant emotional, autonomic, and asthenic disturbances. Mexidol reduces the severity of these disturbances, making it recommended for the treatment of these patients.

Key words: chronic cerebral ischemia; arterial hypertension; atherosclerosis; cognitive impairment; autonomic disorders; asthenia; Mexidol; Mexidol FORTE 250.